Follow Us
Member Of
GI Studies
Study: Synergy
To evaluate plecanatide for treating constipation.
Indication:
Irritable Bowel Syndrome-Constipation (IBS-C)
Key Points:
If patient is eligible, medication is open-label.
Who?
Individuals who have IBS-C but no IBS-D or IBS-M and do not have an obstruction in their digestive track. Also, cannot have a bilirubin or any other laboratory value >3X ULN.
Study: NASH
To evaluate obeticholic acid (OCA) for treating nonalcoholic steatohepatitis fatty liver disease
Indication:
Non-Alcoholic Steatohepatitis
Key Points:
Eligible patients may receive medication or placebo. Lengthy study (1-year treatment and up to 5 years follow-up).
Who?
Patients with fatty liver. (Fatty liver changes seen on CTs). No alcohol abuse. Will need CBC, CMP, BMI and DM to evaluate qualification for study.